Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
You may also be interested in...
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.
US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.